Shares of specialty chemicals manufacturer Tatva Chintan Pharma Chemicals experienced a significant rally on July 20, 2026, hitting the upper circuit with a 20% increase. The stock reached a new 52-week high of Rs 1714, up from its previous close of Rs 1428.45, pushing the company's market capitalization to Rs 3971.27 crore.
This impressive surge followed the announcement of the company's strong first-quarter (Q1) earnings for the period ending June 2026. Tatva Chintan Pharma reported a net profit of Rs 16 crore, marking a substantial 140% increase compared to Rs 6.7 crore in the same quarter last year. Revenue from operations also saw a healthy rise of 43%, reaching Rs 167.1 crore, up from Rs 117 crore year-on-year.
Operational Performance Highlights
The company's operational performance was particularly robust, with EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) climbing 86% to Rs 32.3 crore in Q1, compared to Rs 17.3 crore in the June 2025 quarter. The PAT (Profit After Tax) margin expanded by 68% to 10% in Q1, up from 6% in the corresponding period last year.
Following these positive results, ICICI Securities has maintained its optimistic outlook on Tatva Chintan Pharma, assigning a price target of Rs 1955 for the chemicals stock. The brokerage highlighted the strong operating performance, noting an 86.4% year-on-year and 14.8% sequential increase in EBITDA.
Growth Drivers and Future Outlook
The revenue growth during the quarter was broad-based, with significant contributions from key segments such as Structure Directing Agents (SDA), Phase Transfer Catalysts (PTC), and PASC. While sales of electrolyte salts faced temporary production disruptions, the company anticipates the benefits of price pass-through to be reflected in subsequent quarters.
Management reiterated its guidance for the fiscal year 2027 (FY27), projecting revenue growth of 25-30% and an EBITDA margin of 20-22%. This outlook is supported by improving demand trends and encouraging business momentum across Tatva Chintan Pharma's core product segments, signaling continued positive trajectory for the company.